EU Reverses Stance, Supports Lecanemab for Early Alzheimer's Treatment
TL;DR Summary
The European Medicines Agency has approved Lecanemab, a drug targeting the cause of Alzheimer's disease, marking a potential turning point in its treatment. Developed by BioArctic and Eisai, Lecanemab aims to delay Alzheimer's progression by removing beta-amyloid plaques in the brain. While it offers hope, the drug's benefits are limited, delaying symptoms by about five months, and it poses risks like brain hemorrhages. The approval highlights the ongoing challenges and potential of antibody therapies in Alzheimer's treatment, with further research and infrastructure needed for widespread application.
- Lecanemab: Why This Could Be The Beginning Of The End Of Alzheimer’s Worldcrunch
- EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection Reuters
- European committee takes a second look at Alzheimer's drug and now says it should be approved The Associated Press
- Leqembi recommended for treatment of early Alzheimer’s disease European Medicines Agency |
- Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease Biogen | Investor Relations
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
11 min
vs 12 min read
Condensed
96%
2,304 → 86 words
Want the full story? Read the original article
Read on Worldcrunch